Stay updated on Nivolumab + Celecoxib in Cold Tumors Clinical Trial
Sign up to get notified when there's something new on the Nivolumab + Celecoxib in Cold Tumors Clinical Trial page.

Latest updates to the Nivolumab + Celecoxib in Cold Tumors Clinical Trial page
- Check4 days agoChange DetectedThe NIH banner announcing updates and a transition from “Artificial Intelligence” to “Super Intelligence” is no longer displayed. The study page’s 403 error remains.SummaryDifference1%

- Check11 days agoChange DetectedThe footer’s site revision changed from v3.7.2 to v3.8.0 while the study page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check18 days agoChange DetectedA banner announces NIH website transition updates and says agencies are using “Super Intelligence” in place of “Artificial Intelligence” during the transition.SummaryDifference1%

- Check25 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.1 to v3.7.2, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check32 days agoChange DetectedThe site footer revision number changed from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check53 days agoChange DetectedThe study page now shows a 403 Forbidden error instead of the trial details, blocking access to the main content and navigation typically available for the record.SummaryDifference18%

Stay in the know with updates to Nivolumab + Celecoxib in Cold Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab + Celecoxib in Cold Tumors Clinical Trial page.